Denali Therapeutics Q3 2026 Results: Turns Profitable, Net Income $70.1M
Denali Therapeutics reported a net income of $70.1 million for the third quarter of 2026, driven by a $194.0 million gain from the sale of a priority review voucher. However, the company recorded a net loss of $185.9 million for the first nine months of 2026, reflecting ongoing heavy investment in research and development and the initial recognition of product revenue.
- Key figure
- Net income $70.1M